Product Details
| Product Name:
BMY-25271 |
CAS No.:
78441-82-4 |
| Supply Ability:
10g |
Release date:
2025/10/27 |
Product Introduction
Bioactivity
| Name | BMY-25271 |
| Description | BMY-25271 is an antagonist of histamine H2 receptor. |
| In vivo | The dose-response curves are parallel and oral ED50 values derived from probit analysis are 0.093, 0.97, and 6.9 mg/kg for BMY-25271, ranitidine, and cimetidine, respectively. BMY-25271 is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | HistamineReceptor | Histamine Receptor | Histamine H2 receptor | BMY-25271 | BMY25271 | BMY 25271 |
| Inhibitors Related | Chlorphenesin | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Nizatidine | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:105208-35-3
$0.00 / 5mg
-
CAS:132195-65-4
$1970.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$48.00/5mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-09 |
|
|
$2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-22 |